← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Anabios Corporation
San Diego, CA
$5,129,571
Total funding
6
Grants
Funding over time
peak $1.7M · FY2014–21$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$4,882,110 · 5
FDA$247,461 · 1
By mechanism
R44$4,361,405 · 3
R43$520,705 · 2
U01$247,461 · 1
Investigators at Anabios Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Development of a novel analgesic for mixed inflammatory and neuropathic pain states$1,734,409
R44 · FY2021 · NS
Development of an Integrated Platform for the Use of Adult Human Primary Cardiomyocytes in Preclinical Safety Assessment$1,132,289
R44 · FY2020 · TR
Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds$945,014
R44 · FY2016 · TR
Validation and qualification of an ex vivo human cardiac tissue-based assay for the assessment of the potential cardiotoxicity of pharmaceutical compounds$549,693
R44 · FY2017 · TR
Development of a novel translational pain-drug screening platform for the generation of human-relevant data in preclinical pain drug discovery$320,054
R43 · FY2020 · DA
DEVELOPMENT AND QUALIFICATION OF A BIOMARKER FOR PRECLINICALLY IDENTIFYING THE PRO-ARRHYTHMIA RISK OF DRUGS BASED ON CONTRACTILITY MEASUREMENTS CONDUCTED IN HUMAN ADULT PRIMARY CARDIOMYOCYTES$247,461
U01 · FY2019 · FD
Validation and qualification of an ex vivo human cardiac tissue-based assay for t$200,651
R43 · FY2014 · TR